Current trends in sonothrombolysis for acute ischemic stroke  by Alexandrov, Andrei V.
Perspectives in Medicine (2012) 1, 21—24
Bartels E, Bartels S, Poppert H (Editors):
New Trends in Neurosonology and Cerebral Hemodynamics — an Update.
Perspectives in Medicine (2012) 1, 21—24
j ou rna l homepage : www.e l sev i e r . com/ loca te/pe rmed
Current trends in sonothrombolysis for acute
ischemic stroke
Andrei V. Alexandrov ∗
Comprehensive Stroke Center, University of Alabama Hospital, Birmingham, USA
KEYWORDS
Thrombolysis;
Recanalization;
Stroke;
Outcome
Summary Intravenous tissue plasminogen activator (tPA) remains the only approved, fastest
and widely feasible treatment of acute ischemic stroke. Systemic tPA induces recanalization
of an occluded vessel, the process thought to lead to neurological recovery. Augmentation
of this ﬁbrinolytic activity can be safely achieved with diagnostic ultrasound frequencies and
intensities. Ultrasound delivers mechanical pressure waves to thrombi exposing more thrombus
surface to circulating drug. International multi-center CLOTBUST trial showed that patients
with acute stroke treated with sonothrombolysis (tPA+2MHz TCD) had more dramatic clinical
recovery coupled with arterial recanalization (25% vs 8%) at no increase in the risk of symp-
tomatic intracerebral hemorrhage (sICH). Based on this trial and subsequent phase I—II studies
of a novel operator-independent device for delivery of the CLOBUST levels of ultrasound energy,
a phase III efﬁcacy trial of sonothrombolysis (named CLOTBUSTER) is being launched in Europe
and North America.
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Introduction
Intravenous tissue plasminogen activator (tPA) remains the
only approved therapy for acute ischemic stroke [1] that
can be administered fast and at any level emergency room
equipped with a non-contrast CT scanner. Even though
patients with severe strokes and proximal arterial occlu-
sions are less likely to respond to tPA, they still do
better than placebo-treated patients [1]. The presence
Openof a proximal arterial occlusion should not be viewed as
an insurmountable predictor of tPA failure since nutritious
recanalization can occur even with large middle cerebral
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Open access under CC BY-NC-ND license.MCA) or internal carotid artery (ICA) thrombi [2,3]. Even
f intra-arterial interventions are approved in the future
or stroke treatment, it is unrealistic to expect that all
atients with MCA occlusions either will reach comprehen-
ive stroke centers in time or their risk factor proﬁle would
lways make catheter intervention feasible. With bridging
ntravenous—intra-arterial protocols being tested, there is
ven further need to amplify the systemic part of reperfu-
ion therapy so that more patients could beneﬁt from early
reatment initiation [4].
rterial recanalization and reversibility of
troke
s under CC BY-NC-ND license.arly clinical improvement after stroke usually occurs after
rterial recanalization [5—8]. The so-called ‘‘recanalization
ypothesis’’ links the occurrence of recanalization with
ncrease of good functional outcome and reduction of death
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9], however this hypothesis has not been conﬁrmed in a
rospective clinical trial, subject of an ongoing CLOTBUST-
RO multi-center study [10]. In the CLOTBUST trial [11],
arly recanalization coupled with early dramatic recov-
ry was more common among tPA treated patients who
ere exposed to continuous vs intermittent monitoring with
ulsed wave 2MHz TCD (25% vs 8%). This, in turn, produced
trend towards more patients recovering at 3 months to
odiﬁed Ranking score 0—1 (42% vs 29%) [11].
Diagnosis of an acute intracranial occlusion, re-
analization and re-occlusion in the CLOTBUST trial was
ased on the thrombolysis in brain ischemia (TIBI) residual
ow grading system [12]. It describes typical waveforms that
dentify residual ﬂow around an arterial occlusion, and their
etailed deﬁnitions were published elsewhere [13].
Delivery of tPA to and through the thrombus is depen-
ent on minuscule residual blood cell ﬂow around the
hrombus and plasma ﬂow through the thrombus and the
eed for ultrasound exposure to facilitate drug delivery,
nzymatic and mechanical thrombus dissolution has been
mphasized by many research groups [14—22]. Acute stroke
rovided the clinical setting to test the effect of continu-
us exposure to ultrasound energy in human subjects, goal
ess attainable in acute coronary syndromes. The CLOT-
UST trial demonstrated the positive biological effect of
ow intensity 2MHz pulsed wave transcranial Doppler on
nhancement of tPA-induced early recanalization. It paved
he road for subsequent studies that included combination
f ultrasound with gaseous microspheres [23—29] (Table 1).
etailed analysis of microspheres data is beyond the scope
f this update since at the moment the clinical develop-
ents in the ﬁeld of sonothrombolysis are focused on the
ltrasound device, i.e. drug—device combination. Testing
PA combination with such a device alone is necessary in
he ﬁrst place before more complex combination products
drug—drug—device or drug—device—device) can be tested
i
s
a
s
Table 1 Clinical trials of microsphere-potentiated sonothromboly
(modiﬁed from Ref. [34]).
Trial F Microspheres Design R
Molina et al.
[23]
2MHz Galactose-
based
tPA/TCD/S vs
tPA/TCD vs tPA
Alexandrov
et al. [24]
2MHz Perﬂutren-
lipid
tPA/TCD/S vs
tPA/TCD
TUCSON [25] 2MHz Perﬂutren-
lipid
tPA/TCD/S 2 doses
vs tPA
Larrue et al.
[28]
2MHz Galactose-
based
tPA/TCCD/S vs tPA
Perren et al.
[26]
2MHz Phospholipid
encapsulated
sulphur
hexaﬂuoride
tPA/TCCD/S vs tPA
Nicoli et al.
[29]
2MHz Phospholipid
encapsulated
sulphur
hexaﬂuoride
tPA/TCD/S vs
tPA/TCD
F — frequency of ultrasound; ICH — intracerebral hemorrhage; tPA —
microspheres; mRS — modiﬁed Rankin scale; TCCD — transcranial colorA.V. Alexandrov
n clinical trials of microspheres activated with ultrasound
n the presence of tPA.
LOTBUST levels of ultrasound energy and an
perator independent device
he main limitation of TCD technology used in the CLOT-
UST trial is its extreme operator dependency and the need
or a qualiﬁed sonographer to be present at bedside to ﬁnd,
im and deliver ultrasound beam to the thrombus residual
ow interface. Our collaborative group ﬁrst measured out-
uts of all devices used in the CLOTBUST trial [30], then
esigned multi-transducer assembly to cover conventional
indows used for TCD examinations [31], and prospectively
valuated its safety in human volunteers [35] and ischemic
troke patients treated with intravenous tPA [36]. In these
hase I—II clinical studies, the novel operator-independent
evice showed no safety concerns, caused no disruption
f the blood—brain barrier on sequential MRI imaging and
ielded recanalization rates comparable to the CLOTBUST
rial.
Since this operator-independent device can be quickly
ounted by medical personnel with no prior experience in
ltrasound, the device enables us to conduct large scale
onothrombolysis trials at all levels of emergency rooms
apable of administering tPA as the standard of care. Thus,
onothrombolysis for acute ischemic stroke enters testing in
he pivotal efﬁcacy multi-national trial called CLOTBUSTER
Combined Lysis of ThromBus using 2MHz pulsed wave Ultra-
ound and Systemic TPA for Emergent Revascularization,
CT01098981). Brieﬂy, all patients will receive 0.9mg/kg
ntravenous tPA therapy (10% bolus, 90% continuous infu-
ion over 1 h, maximum dose 90mg) as standard of care
ccording to national labels (i.e. within 3 or 4.5 h from
ymptom onset). All patients with National Institutes of
sis for acute ischemic stroke using trancranial ultrasonography
ecanalization Asymptomatic
ICH
Symptomatic
ICH
Outcome
55% 23% 3% 56% (mRS 0—2)
42% 25% 0% 40% (mRS 0—1)
67% 17% 0%, 27% 75% (mRS 0—1)
48% 78% 0% N/A
63% N/A 9% N/A
86% N/A 5.7% N/A
tissue plasminogen activator; TCD — transcranial Doppler; S —
-coded duplex; N/A — not available.
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Health Stroke Scale (NIHSS) scores≥ 10 points are eligible
and after signing a written informed consent they will wear
an operator-independent ultrasound emitting device for 2 h.
The proprietary device (Cerevast Therapeutics, Redmond,
WA) exposes traditional transcranial Doppler bone windows
for sequential insonation of the 12 proximal intracranial
segments that most commonly contain thrombo-embolic
occlusions causing disabling strokes. Patients will be ran-
domized 1:1 to continuous exposure to 2MHz PW ultrasound
versus sham exposure. No pre-treatment proof of a proximal
arterial occlusion would be required since angiography is not
a standard of care for evaluation of tPA-eligible patients at
most institutions. Furthermore, NIHSS≥ 10 points identify
severe cerebral ischemia caused by proximal occlusions in
>80% of patients [32,33].
Safety will be determined by the incidence of sICH within
24 h of treatment. Functional recovery will be determined
bymodiﬁed Ranking scores (primary end-point mRS 0—1) at 3
months. CLOTBUSTER is a large simple efﬁcacy clinical trial,
the ﬁrst of its kind for sonothrombolysis.
Once CLOTBUSTER establishes safety and efﬁcacy of an
operator-independent 2MHz PW ultrasound device, the next
phase clinical trials can commence combining experimen-
tal microspheres with regulatory-approved tPA therapy and
safe ultrasound exposure. This exposure is needed to acti-
vate microspheres, however a proof of safety and efﬁcacy of
ultrasound is required before a complex combinatory treat-
ment with or without tPA can be tested any further in the
clinical setting.
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